NCT02135133 2026-03-17
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
55 trialsNCT01496976 2025-12-19
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01437709 2025-02-28
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02388048 2025-01-29
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT01243190 2024-09-19
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02199184 2024-06-11
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01527149 2024-02-07
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Roswell Park Cancer Institute
Phase 2 Completed
NCT01145209 2023-11-28
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01060384 2023-10-04
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT02004522 2023-09-21
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
SecuraBio
Phase 3 Completed
NCT02049515 2023-09-21
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
SecuraBio
Phase 3 Completed
NCT02710643 2022-06-21
FIL_MIRO
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT01481272 2021-12-27
PLRG8
Polish Lymphoma Research Group
Phase 2 Completed
NCT01190449 2021-08-18
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01444716 2021-07-26
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01613300 2021-05-26
Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT01363128 2021-05-03
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01497496 2021-04-27
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT01329900 2020-07-08
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02689141 2020-06-11
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
Phase 2 Completed
NCT01578707 2019-12-18
RESONATEâ„¢
Pharmacyclics LLC.
Phase 3 Completed
NCT01532700 2019-09-24
An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
University Health Network, Toronto
Phase 2 Completed
NCT01002755 2019-05-07
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01024010 2018-09-18
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Completed
NCT01294579 2018-08-09
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Novartis
Phase 2 Completed
NCT01191190 2018-05-08
CRC027
University of California, San Diego
Phase 2 Completed
NCT01171378 2018-04-25
CHOP-OR
University of Oxford
Phase 2 Completed
NCT01515176 2018-03-15
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01626352 2017-11-22
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00742144 2017-11-17
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 1 Completed
NCT01110031 2017-11-13
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
GlaxoSmithKline
Phase 1 Completed
NCT01848145 2017-06-06
Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00811733 2017-05-30
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
GlaxoSmithKline
Phase 2 Completed
NCT01077622 2017-05-30
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01580228 2017-02-23
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01520922 2017-01-19
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Phase 2 Completed
NCT01113632 2016-09-20
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01809847 2016-09-19
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation
Technische Universität Dresden
Phase 2 Completed
NCT02412267 2016-03-23
DLBL
National Cancer Centre, Singapore
Phase 2 Completed
NCT01195766 2016-02-24
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT01187303 2015-11-02
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
University of Cologne
Phase 2 Completed
NCT01563055 2015-08-10
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01014208 2015-08-07
ORCHARRD
GlaxoSmithKline
Phase 3 Completed
NCT00622388 2015-07-24
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
GlaxoSmithKline
Phase 2 Completed
NCT01217749 2015-06-25
PCYC-1109-CA
Pharmacyclics LLC.
Phase 1/2 Completed
NCT01310101 2015-02-03
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
Brno University Hospital
Phase 2 Completed
NCT00494780 2014-07-11
MUNIN
GlaxoSmithKline
Phase 2 Completed
NCT01453062 2014-07-08
Phase IV Observational Study in Chronic Lymphocytic Leukemia
GlaxoSmithKline
Completed
NCT00349349 2014-06-04
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
GlaxoSmithKline
Phase 2 Completed